Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Eric Wu

Concepts (357)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
28
2022
381
3.990
 Why?
Everolimus
10
2016
61
2.580
 Why?
Health Resources
8
2022
122
2.410
 Why?
Cost of Illness
12
2022
254
2.190
 Why?
Receptor, ErbB-2
9
2016
300
1.600
 Why?
Breast Neoplasms
12
2016
1862
1.540
 Why?
Medication Adherence
6
2016
536
1.280
 Why?
Hyperkalemia
2
2020
26
1.260
 Why?
Receptors, Estrogen
3
2015
372
1.250
 Why?
Receptors, Antigen, T-Cell
4
2021
615
1.240
 Why?
Immunotherapy, Adoptive
2
2020
184
1.220
 Why?
Health Expenditures
6
2020
171
1.090
 Why?
Practice Patterns, Physicians'
4
2016
1177
1.070
 Why?
Health Services
6
2016
103
0.980
 Why?
United States
39
2022
12186
0.950
 Why?
Receptors, Progesterone
2
2015
319
0.870
 Why?
Models, Economic
2
2020
48
0.850
 Why?
Hepatitis C, Chronic
2
2015
151
0.850
 Why?
Middle Aged
52
2020
26738
0.840
 Why?
Antifungal Agents
4
2017
128
0.810
 Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
98
0.800
 Why?
Antineoplastic Agents
9
2016
1879
0.790
 Why?
Aged
38
2022
19074
0.780
 Why?
Retrospective Studies
31
2022
12556
0.770
 Why?
Hospital Costs
3
2020
104
0.740
 Why?
Antineoplastic Combined Chemotherapy Protocols
9
2016
1356
0.730
 Why?
Gout
2
2012
36
0.720
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
256
0.700
 Why?
Female
63
2021
59523
0.680
 Why?
Nocturia
1
2019
7
0.680
 Why?
Hospitalization
13
2021
1752
0.660
 Why?
Proportional Hazards Models
12
2017
1075
0.640
 Why?
Kaplan-Meier Estimate
10
2017
811
0.630
 Why?
Cost-Benefit Analysis
12
2022
544
0.630
 Why?
Depressive Disorder, Major
3
2011
301
0.620
 Why?
Nutrition Surveys
1
2019
224
0.610
 Why?
Humans
80
2022
114709
0.600
 Why?
Male
53
2021
55609
0.600
 Why?
Proline
2
2015
72
0.590
 Why?
Candida
2
2017
32
0.590
 Why?
Adult
41
2022
30554
0.580
 Why?
Prevalence
10
2020
2251
0.570
 Why?
Medicare
7
2022
665
0.570
 Why?
Fluconazole
1
2017
16
0.570
 Why?
Candidemia
1
2017
7
0.570
 Why?
Myocardial Perfusion Imaging
1
2017
34
0.560
 Why?
Cardiologists
1
2017
40
0.550
 Why?
Tomography, Emission-Computed, Single-Photon
1
2017
76
0.550
 Why?
Fees, Pharmaceutical
3
2016
13
0.550
 Why?
Oligopeptides
2
2015
236
0.540
 Why?
Thrombolytic Therapy
1
2017
117
0.530
 Why?
Renal Insufficiency, Chronic
2
2020
486
0.530
 Why?
Insurance Claim Review
8
2017
67
0.520
 Why?
Antirheumatic Agents
2
2016
255
0.520
 Why?
Biological Therapy
1
2016
26
0.510
 Why?
Hypoglycemic Agents
2
2015
1013
0.510
 Why?
Citalopram
3
2011
27
0.500
 Why?
Databases, Factual
8
2016
1125
0.500
 Why?
Drug Eruptions
1
2015
26
0.500
 Why?
Tissue Plasminogen Activator
1
2017
225
0.490
 Why?
Psoriasis
3
2012
74
0.480
 Why?
Fibrinolytic Agents
1
2017
234
0.480
 Why?
Comparative Effectiveness Research
2
2012
130
0.480
 Why?
Liver Neoplasms
2
2015
506
0.470
 Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
299
0.470
 Why?
Diphosphonates
2
2012
51
0.470
 Why?
Delivery of Health Care
2
2019
833
0.460
 Why?
Physicians, Primary Care
1
2017
222
0.460
 Why?
Anemia
1
2015
143
0.450
 Why?
Brain Ischemia
1
2017
299
0.450
 Why?
Imidazoles
2
2012
208
0.440
 Why?
Antiviral Agents
2
2015
645
0.420
 Why?
Dextroamphetamine
1
2012
3
0.410
 Why?
Aged, 80 and over
11
2020
6347
0.400
 Why?
Referral and Consultation
1
2017
635
0.400
 Why?
Methylphenidate
1
2012
36
0.400
 Why?
Hypertension
4
2018
1056
0.400
 Why?
Drug Delivery Systems
1
2015
296
0.400
 Why?
Pulmonary Embolism
1
2014
181
0.390
 Why?
Drug Costs
6
2015
92
0.390
 Why?
Schizophrenia
2
2006
414
0.390
 Why?
Neoplasm Metastasis
6
2016
523
0.390
 Why?
Fumarates
1
2011
10
0.370
 Why?
Drugs, Generic
1
2011
18
0.370
 Why?
Drug Substitution
1
2011
46
0.360
 Why?
Central Nervous System Stimulants
1
2012
139
0.360
 Why?
Postmenopause
4
2016
303
0.360
 Why?
Bone Diseases
1
2011
57
0.360
 Why?
Venous Thromboembolism
1
2014
231
0.350
 Why?
Stroke
2
2017
1022
0.350
 Why?
Angiotensin Receptor Antagonists
1
2011
76
0.350
 Why?
Amides
1
2011
86
0.350
 Why?
Arthritis, Rheumatoid
2
2016
1003
0.350
 Why?
Diabetes Mellitus, Type 2
2
2015
2096
0.340
 Why?
Diabetes Mellitus
1
2018
900
0.340
 Why?
Multiple Myeloma
1
2011
98
0.340
 Why?
Anticoagulants
1
2014
550
0.340
 Why?
Crohn Disease
5
2012
196
0.330
 Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
179
0.330
 Why?
Insurance, Health
3
2011
244
0.330
 Why?
Antibodies, Monoclonal
6
2011
1264
0.320
 Why?
Sick Leave
2
2007
12
0.320
 Why?
Risk Factors
12
2017
8634
0.320
 Why?
Hyperuricemia
1
2009
43
0.320
 Why?
Quality of Life
8
2021
2353
0.320
 Why?
Heart Failure
2
2020
1945
0.320
 Why?
Patient Acceptance of Health Care
7
2021
681
0.310
 Why?
Disease-Free Survival
5
2016
620
0.310
 Why?
Antineoplastic Agents, Hormonal
3
2016
138
0.310
 Why?
Attention Deficit Disorder with Hyperactivity
1
2012
364
0.310
 Why?
Costs and Cost Analysis
7
2019
196
0.310
 Why?
Absenteeism
2
2005
40
0.300
 Why?
Comorbidity
8
2014
1448
0.300
 Why?
Uric Acid
1
2009
148
0.300
 Why?
Neoplasm Recurrence, Local
2
2015
859
0.300
 Why?
Insulin
2
2015
2080
0.300
 Why?
Head and Neck Neoplasms
1
2012
427
0.290
 Why?
Physicians
1
2015
772
0.290
 Why?
Insurance Claim Reporting
2
2007
22
0.290
 Why?
Hypoglycemia
1
2012
387
0.280
 Why?
Young Adult
12
2020
10472
0.270
 Why?
Triazoles
3
2016
131
0.270
 Why?
Health Status Indicators
1
2007
156
0.270
 Why?
Pentosan Sulfuric Polyester
1
2006
1
0.260
 Why?
Economics, Pharmaceutical
1
2006
10
0.260
 Why?
Cystitis, Interstitial
1
2006
16
0.260
 Why?
Drug Resistance, Fungal
2
2017
9
0.260
 Why?
Endometriosis
2
2017
40
0.250
 Why?
Prostatic Neoplasms
2
2012
921
0.240
 Why?
Urinary Incontinence
1
2005
56
0.240
 Why?
Immunoglobulin G
1
2008
770
0.240
 Why?
Recurrence
3
2020
935
0.230
 Why?
Treatment Outcome
12
2017
9088
0.230
 Why?
Psychotic Disorders
1
2005
118
0.220
 Why?
Antibodies, Monoclonal, Humanized
7
2012
663
0.220
 Why?
Drug Therapy, Combination
4
2015
951
0.210
 Why?
Population Surveillance
1
2005
392
0.200
 Why?
Adolescent
17
2017
17855
0.190
 Why?
Anti-Inflammatory Agents
3
2011
447
0.190
 Why?
Biological Products
2
2016
166
0.190
 Why?
Bone Density Conservation Agents
2
2012
62
0.190
 Why?
Gastritis
1
2022
84
0.190
 Why?
Giant Cell Tumor of Tendon Sheath
1
2021
2
0.190
 Why?
Enteritis
1
2022
82
0.190
 Why?
Adenocarcinoma
1
2007
795
0.180
 Why?
Gout Suppressants
2
2012
20
0.180
 Why?
Hemophilia B
1
2021
36
0.180
 Why?
Tumor Necrosis Factor-alpha
4
2009
1140
0.180
 Why?
Hemophilia A
1
2021
69
0.180
 Why?
Eosinophilia
1
2022
186
0.170
 Why?
Genetic Therapy
1
2021
257
0.170
 Why?
National Health Programs
1
2019
20
0.170
 Why?
Voriconazole
2
2016
24
0.170
 Why?
Technology Assessment, Biomedical
1
2019
29
0.170
 Why?
Regression Analysis
4
2012
945
0.170
 Why?
Idiopathic Pulmonary Fibrosis
2
2015
505
0.170
 Why?
Myelodysplastic Syndromes
1
2021
119
0.160
 Why?
Aging
1
2009
1618
0.160
 Why?
Microbial Sensitivity Tests
2
2017
300
0.160
 Why?
Nitriles
2
2016
149
0.150
 Why?
Treatment Failure
2
2017
331
0.150
 Why?
Overweight
1
2022
472
0.150
 Why?
Vital Capacity
2
2015
255
0.150
 Why?
Emergency Service, Hospital
3
2014
1820
0.150
 Why?
Polystyrenes
1
2018
36
0.150
 Why?
Mental Disorders
1
2005
893
0.140
 Why?
Potassium
1
2018
128
0.140
 Why?
4-Aminopyridine
1
2017
21
0.140
 Why?
Antihypertensive Agents
2
2011
429
0.140
 Why?
Retreatment
1
2017
67
0.140
 Why?
Patient Compliance
2
2011
525
0.140
 Why?
Administration, Intravenous
1
2017
124
0.140
 Why?
Aspergillosis
1
2016
23
0.140
 Why?
Consumer Behavior
1
2017
65
0.140
 Why?
Abiraterone Acetate
1
2016
14
0.140
 Why?
Hysterectomy
1
2017
106
0.130
 Why?
Chronic Disease
3
2014
1578
0.130
 Why?
Administrative Claims, Healthcare
1
2016
22
0.130
 Why?
Health Care Rationing
1
2016
45
0.130
 Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
40
0.130
 Why?
Aromatase Inhibitors
1
2016
49
0.130
 Why?
Time-to-Treatment
1
2017
147
0.130
 Why?
Ambulatory Care
3
2015
478
0.130
 Why?
Capecitabine
1
2016
45
0.130
 Why?
Clinical Protocols
1
2017
233
0.130
 Why?
Patient Admission
1
2017
176
0.130
 Why?
Prednisone
1
2016
229
0.130
 Why?
Disability Evaluation
1
2017
271
0.130
 Why?
Waiting Lists
1
2017
211
0.120
 Why?
International Classification of Diseases
1
2016
116
0.120
 Why?
Logistic Models
2
2014
1841
0.120
 Why?
Cross-Sectional Studies
3
2019
4410
0.120
 Why?
Ki-1 Antigen
1
2015
4
0.120
 Why?
Androstadienes
1
2015
97
0.120
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
16
0.120
 Why?
Drug Interactions
1
2016
338
0.120
 Why?
California
2
2006
353
0.120
 Why?
Follow-Up Studies
5
2015
4411
0.120
 Why?
Leukemia, Myeloid, Acute
1
2021
534
0.120
 Why?
Ribavirin
1
2015
89
0.120
 Why?
Drug Administration Schedule
3
2011
718
0.110
 Why?
International Normalized Ratio
1
2014
45
0.110
 Why?
Recombinant Proteins
1
2017
1230
0.110
 Why?
Heparin, Low-Molecular-Weight
1
2014
28
0.110
 Why?
Amphotericin B
1
2014
29
0.110
 Why?
Insurance, Health, Reimbursement
1
2014
88
0.110
 Why?
Immunoconjugates
1
2015
87
0.110
 Why?
Constipation
1
2014
76
0.110
 Why?
Pulmonary Disease, Chronic Obstructive
2
2011
916
0.110
 Why?
Drug Prescriptions
1
2015
239
0.110
 Why?
Recovery of Function
1
2017
574
0.110
 Why?
China
1
2014
161
0.110
 Why?
ErbB Receptors
2
2016
554
0.110
 Why?
Mycoses
1
2014
67
0.110
 Why?
Morpholines
1
2014
102
0.110
 Why?
Models, Theoretical
1
2017
515
0.110
 Why?
Pyridines
1
2016
425
0.110
 Why?
Thiophenes
1
2014
108
0.110
 Why?
Drug Combinations
2
2011
287
0.110
 Why?
Hodgkin Disease
1
2015
121
0.110
 Why?
Warfarin
1
2014
135
0.110
 Why?
Budgets
1
2012
14
0.110
 Why?
Laparoscopy
1
2017
398
0.110
 Why?
Allopurinol
1
2012
53
0.100
 Why?
Multivariate Analysis
4
2015
1430
0.100
 Why?
Gastrointestinal Diseases
1
2014
182
0.100
 Why?
Health Status
2
2008
722
0.100
 Why?
Adalimumab
5
2011
44
0.100
 Why?
Lisdexamfetamine Dimesylate
1
2012
4
0.100
 Why?
Multiple Sclerosis
1
2017
376
0.100
 Why?
Estradiol
1
2015
455
0.100
 Why?
Neoplasm Staging
1
2015
1167
0.100
 Why?
Rivaroxaban
1
2014
211
0.100
 Why?
Databases as Topic
2
2009
63
0.100
 Why?
Immunocompromised Host
1
2014
195
0.100
 Why?
Patient Readmission
1
2017
610
0.100
 Why?
Medicaid
2
2006
407
0.100
 Why?
Sulfonylurea Compounds
1
2012
44
0.100
 Why?
Sirolimus
1
2012
181
0.100
 Why?
Communication
1
2017
744
0.090
 Why?
Models, Statistical
2
2012
599
0.090
 Why?
Fractures, Spontaneous
1
2011
13
0.090
 Why?
Spinal Cord Compression
1
2011
17
0.090
 Why?
Hypercalcemia
1
2011
20
0.090
 Why?
Cost Sharing
1
2011
14
0.090
 Why?
Efficiency
2
2011
84
0.090
 Why?
Japan
2
2021
86
0.090
 Why?
Bone Diseases, Metabolic
1
2011
53
0.090
 Why?
Bone Neoplasms
1
2012
194
0.090
 Why?
Antidepressive Agents, Second-Generation
1
2010
38
0.090
 Why?
Severity of Illness Index
4
2012
2540
0.090
 Why?
Surveys and Questionnaires
3
2021
4624
0.090
 Why?
Obesity
1
2022
2508
0.090
 Why?
Bronchodilator Agents
1
2011
239
0.080
 Why?
Angiogenesis Inhibitors
1
2011
214
0.080
 Why?
Administration, Oral
1
2012
728
0.080
 Why?
Linear Models
1
2012
768
0.080
 Why?
Antidepressive Agents
1
2011
195
0.080
 Why?
Case-Control Studies
2
2014
3004
0.080
 Why?
Gastrointestinal Agents
1
2009
60
0.080
 Why?
Etanercept
1
2008
51
0.080
 Why?
Time Factors
2
2017
6116
0.080
 Why?
Blood Chemical Analysis
1
2009
90
0.080
 Why?
Age Distribution
3
2015
342
0.080
 Why?
Receptors, Tumor Necrosis Factor
1
2008
140
0.080
 Why?
Employment
2
2007
137
0.070
 Why?
Clinical Trials as Topic
1
2012
932
0.070
 Why?
Digestive System Surgical Procedures
1
2008
91
0.070
 Why?
Quality-Adjusted Life Years
2
2022
101
0.070
 Why?
Child
4
2020
18422
0.070
 Why?
Veterans Disability Claims
1
2006
1
0.070
 Why?
Health Benefit Plans, Employee
1
2006
20
0.070
 Why?
Private Sector
1
2006
51
0.070
 Why?
Coronary Disease
1
2008
348
0.060
 Why?
Cohort Studies
2
2012
4895
0.060
 Why?
Employer Health Costs
1
2005
4
0.060
 Why?
Metabolic Diseases
1
2007
98
0.060
 Why?
Ischemic Attack, Transient
1
2006
62
0.060
 Why?
Hallucinations
1
2005
30
0.060
 Why?
Colorectal Neoplasms
1
2011
615
0.060
 Why?
Area Under Curve
1
2005
274
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
961
0.060
 Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
230
0.060
 Why?
Metabolic Syndrome
1
2007
321
0.060
 Why?
Asthma
2
2007
2029
0.060
 Why?
Age Factors
2
2015
2894
0.060
 Why?
Adrenal Cortex Hormones
1
2007
497
0.060
 Why?
Data Collection
1
2006
620
0.050
 Why?
Lung
1
2015
3561
0.050
 Why?
Psychiatric Status Rating Scales
1
2005
482
0.050
 Why?
Drug Resistance, Neoplasm
1
2007
638
0.050
 Why?
Interviews as Topic
1
2005
583
0.050
 Why?
Anti-Asthmatic Agents
1
2006
349
0.050
 Why?
Health Policy
1
2005
334
0.050
 Why?
Glucagon-Like Peptides
1
2022
22
0.050
 Why?
Mental Health Services
1
2005
317
0.050
 Why?
Double-Blind Method
3
2011
1660
0.050
 Why?
Incidence
1
2006
2313
0.040
 Why?
Asia
1
2019
53
0.040
 Why?
Disease Progression
2
2015
2381
0.040
 Why?
Administration, Inhalation
2
2011
641
0.040
 Why?
Potassium Channel Blockers
1
2017
29
0.040
 Why?
Disease Management
2
2015
560
0.040
 Why?
Models, Econometric
1
2016
34
0.030
 Why?
Delayed-Action Preparations
1
2017
159
0.030
 Why?
Itraconazole
1
2016
7
0.030
 Why?
B-Lymphocytes
1
2020
766
0.030
 Why?
Cardiovascular Diseases
1
2007
1727
0.030
 Why?
Utilization Review
1
2014
34
0.030
 Why?
Early Diagnosis
1
2015
217
0.030
 Why?
Dose-Response Relationship, Drug
2
2009
1842
0.030
 Why?
Hypothyroidism
1
2014
64
0.030
 Why?
Forced Expiratory Volume
1
2015
475
0.030
 Why?
Aspergillus
1
2014
16
0.030
 Why?
Cryptococcus
1
2014
8
0.030
 Why?
Anemia, Iron-Deficiency
1
2014
53
0.030
 Why?
Peripheral Vascular Diseases
1
2014
97
0.030
 Why?
Mood Disorders
1
2014
112
0.030
 Why?
Acute Disease
1
2015
911
0.030
 Why?
Biopsy
1
2015
1036
0.020
 Why?
Molecular Targeted Therapy
1
2015
347
0.020
 Why?
Risk
1
2014
812
0.020
 Why?
Matched-Pair Analysis
1
2011
33
0.020
 Why?
Critical Care
1
2015
476
0.020
 Why?
Nervous System Diseases
1
2014
256
0.020
 Why?
Length of Stay
1
2015
962
0.020
 Why?
Cetuximab
1
2011
90
0.020
 Why?
Bevacizumab
1
2011
115
0.020
 Why?
Tablets
1
2010
36
0.020
 Why?
State Medicine
1
2009
18
0.020
 Why?
Sex Factors
1
2015
1715
0.020
 Why?
Epidemiologic Methods
1
2009
72
0.020
 Why?
Remission Induction
1
2009
233
0.020
 Why?
United Kingdom
1
2009
226
0.020
 Why?
Insurance Coverage
1
2010
200
0.020
 Why?
Injections, Subcutaneous
1
2009
134
0.020
 Why?
Maximum Tolerated Dose
1
2009
183
0.020
 Why?
Odds Ratio
1
2011
953
0.020
 Why?
Europe
1
2009
334
0.020
 Why?
Probability
1
2009
289
0.020
 Why?
Statistics, Nonparametric
1
2009
385
0.020
 Why?
Longitudinal Studies
1
2014
2387
0.020
 Why?
Canada
1
2009
322
0.020
 Why?
Prognosis
1
2015
3330
0.020
 Why?
Confidence Intervals
1
2008
305
0.020
 Why?
Reference Values
1
2009
743
0.020
 Why?
Sex Distribution
1
2008
337
0.020
 Why?
Randomized Controlled Trials as Topic
1
2012
1214
0.020
 Why?
Models, Biological
1
2014
1621
0.020
 Why?
Tomography, X-Ray Computed
1
2015
2286
0.020
 Why?
Health Status Disparities
1
2008
200
0.020
 Why?
Infant
2
2007
7964
0.010
 Why?
Child, Preschool
2
2007
9119
0.010
 Why?
Emergency Medical Services
1
2007
590
0.010
 Why?
Risk Assessment
1
2009
2968
0.010
 Why?
Body Mass Index
1
2007
1959
0.010
 Why?
Infant, Newborn
1
2006
5047
0.010
 Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (357) concept(s)
_
Co-Authors Expand Description
See all (2) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)